Enbrel manufacturing facility receives FDA approval

Since mid-December, the estimated 40,000 patients on a waiting list were able to begin Enbrel treatment as a result of production by a plant in Germany. On December 23, 2002, the U.S. Food and Drug Administration (FDA) approved a new Enbrel manufacturing facility located in Rhode Island. Based on approval of this Rhode Island facility, the manufacturers of Enbrel will have the ability to fulfill all new prescription orders. Enbrel is approved for treatment of both adult and juvenile rheumatoid arthritis, as well as psoriatic arthritis.

In order for patients to receive Enbrel, an enrollment program is still in effect. The number for that program is (888) 436-2725.